NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful survival benefit vs chemo for advanced ESCC

Share :
Published: 25 Jan 2023
Views: 94
Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan

Dr Ken Kato speaks to ecancer as part of ASCO GI 2022 about the 29 month follow-up results to the CheckMate 648 study.

The study looked at NIVO (nivolumab) plus chemo (chemotherapy) or IPI (ipilimumab) vs chemotherapy as first-line treatment for advanced oesophageal squamous cell carcinoma.

Dr Kato reports that after the long term follow up the efficacy of the chemo plus NIVO and IPI plus NIVO arms were consistently superior to chemo alone.